Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.27)
# 464
Out of 4,734 analysts
208
Total ratings
38.22%
Success rate
25.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Reiterates: Overweight | $21 | $9.51 | +120.82% | 7 | Jan 15, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $80 → $76 | $45.25 | +67.96% | 17 | Jan 15, 2025 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $6.58 | +340.73% | 13 | Jan 2, 2025 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $24.61 | +172.25% | 14 | Jan 2, 2025 | |
| AQST Aquestive Therapeutics | Initiates: Overweight | $17 | $3.21 | +429.60% | 1 | Dec 17, 2024 | |
| ESPR Esperion Therapeutics | Initiates: Overweight | $8 | $2.15 | +272.09% | 1 | Dec 17, 2024 | |
| QURE uniQure | Maintains: Overweight | $28 → $58 | $14.91 | +289.00% | 9 | Dec 10, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $25 | $21.81 | +14.63% | 6 | Dec 10, 2024 | |
| CDXS Codexis | Reiterates: Overweight | $11 | $5.05 | +117.82% | 6 | Nov 22, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $1.53 | +357.52% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $30 | $14.06 | +113.37% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $152 → $167 | $116.79 | +42.99% | 13 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $116 | $41.28 | +181.01% | 16 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.19 | +246.82% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $85 | $60.52 | +40.45% | 7 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.99 | +134.11% | 9 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $2.70 | +418.52% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $49.17 | +36.26% | 5 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $4.56 | +185.09% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $16.16 | +23.76% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.00 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.49 | +921.87% | 3 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.30 | +1,515.38% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.59 | +919.71% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $2.30 | +771.46% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $4.05 | +467.90% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $4.33 | +315.70% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.84 | +4,770.52% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $5.76 | +6,844.44% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.92 | +2,810.96% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $0.32 | +21,652.64% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $2.10 | +2,042.86% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.75 | +1,367.25% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $2.05 | +2,826.83% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.81 | +4,872.38% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $2.87 | +87,704.88% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.76 | +20,831.45% | 1 | Jan 9, 2020 |
Amicus Therapeutics
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $9.51
Upside: +120.82%
PTC Therapeutics
Jan 15, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $45.25
Upside: +67.96%
89bio
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $6.58
Upside: +340.73%
Celldex Therapeutics
Jan 2, 2025
Reiterates: Overweight
Price Target: $67
Current: $24.61
Upside: +172.25%
Aquestive Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.21
Upside: +429.60%
Esperion Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.15
Upside: +272.09%
uniQure
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $14.91
Upside: +289.00%
Rigel Pharmaceuticals
Dec 10, 2024
Maintains: Neutral
Price Target: $15 → $25
Current: $21.81
Upside: +14.63%
Codexis
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $5.05
Upside: +117.82%
Taysha Gene Therapies
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.53
Upside: +357.52%
Nov 14, 2024
Maintains: Overweight
Price Target: $25 → $30
Current: $14.06
Upside: +113.37%
Nov 7, 2024
Upgrades: Overweight
Price Target: $152 → $167
Current: $116.79
Upside: +42.99%
Nov 6, 2024
Reiterates: Overweight
Price Target: $116
Current: $41.28
Upside: +181.01%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.19
Upside: +246.82%
Oct 15, 2024
Reiterates: Overweight
Price Target: $85
Current: $60.52
Upside: +40.45%
Oct 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.99
Upside: +134.11%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $2.70
Upside: +418.52%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $49.17
Upside: +36.26%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $4.56
Upside: +185.09%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $16.16
Upside: +23.76%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.00
Upside: -
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.49
Upside: +921.87%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.30
Upside: +1,515.38%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.59
Upside: +919.71%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $2.30
Upside: +771.46%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $4.05
Upside: +467.90%
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $4.33
Upside: +315.70%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.84
Upside: +4,770.52%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $5.76
Upside: +6,844.44%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.92
Upside: +2,810.96%
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $0.32
Upside: +21,652.64%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $2.10
Upside: +2,042.86%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.75
Upside: +1,367.25%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $2.05
Upside: +2,826.83%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.81
Upside: +4,872.38%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $2.87
Upside: +87,704.88%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.76
Upside: +20,831.45%